Dr. Adrien A. Eshraghi, MD

Dr. Eshraghi practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Eshraghi's NPI, 1740213958, was assigned on July 9, 2006. Dr. Eshraghi graduated from Paris VI University School of Medicine in 1995. Dr. Eshraghi holds Florida license ME88900.

Dr. Eshraghi's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Eshraghi's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Eshraghi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Eshraghi practices, 2 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Eshraghi's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Eshraghi is board certified in neurotology by the American Board of Otolaryngology - Head and Neck Surgery. Dmand AI has Dr. Eshraghi's licenses on file in 2 states: Florida and California.

Dmand AI lists chronic ear infection, ear eustachian tube disorders, ear infection, hearing loss and impairment, tinnitus and vertigo among the conditions Dr. Eshraghi treats.

CMS data shows 361 Medicare services from Dr. Eshraghi across 7 procedure codes in 2024, for 216 Medicare patients. Medicare paid $22,959 for them.

CMS counts 216 Medicare patients who saw Dr. Eshraghi in 2024. The largest group is 65 to 74, with 99 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.35, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Eshraghi's median patient age at 69, with 53% women.

In 2024, Dr. Eshraghi wrote 137 Medicare Part D claims for 64 patients. 87% of them were for generic drugs. CMS names the drug for 83 of them, across 4 drugs with 11 or more claims each, at $3,713 in total drug cost. In 2023, CMS named 97 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Eshraghi for performance year 2024, reported as part of a group. Dr. Eshraghi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 158 papers to Dr. Eshraghi, published from 2006 to 2025. 2020 was the busiest year, with 15. The most frequent topics are Cochlear Implantation, Hearing Loss and Hair Cells, Auditory. Dr. Eshraghi has published most often in Otol Neurotol. Dr. Eshraghi's most frequent co-authors are Fred F. Telischi, MD, Simon I. Angeli, MD and Christine Thuyvan Dinh, MD.

CMS Open Payments shows 104 general payments to Dr. Eshraghi from 12 drug and device companies from 2016 to 2025. Travel and lodging make up the largest share, 54% of the total. MED-EL Corporation paid the most, $47,895.

Dmand AI lists 9 awards for Dr. Eshraghi, most recently CMS Stage 1 EHR in 2013.

Dr. Eshraghi graduated from Paris VI University School of Medicine in 1995.

Dr. Eshraghi is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.